rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - Антинеопластични средства - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
remiffentanil hospira 1 mg powder for concentrate for injection/infusion
hospira uk ltd. - Ремифентанил - 1 mg powder for concentrate for injection/infusion
remiffentanil hospira 2 mg powder for concentrate for injection/infusion
hospira uk ltd. - Ремифентанил - 2 mg powder for concentrate for injection/infusion
remiffentanil hospira 5 mg powder for concentrate for injection/infusion
hospira uk ltd. - Ремифентанил - 5 mg powder for concentrate for injection/infusion
fentoril 50 micrograms/ml solution for injection
СОФАРМА АД - Фентанил - 50 micrograms/ml solution for injection
victanyl 25 micrograms/h transdermal patch
actavis group ptc ehf - Фентанил - 25 micrograms/h transdermal patch
victanyl 50 micrograms/h transdermal patch
actavis group ptc ehf - Фентанил - 50 micrograms/h transdermal patch
victanyl 75 micrograms/h transdermal patch
actavis group ptc ehf - Фентанил - 75 micrograms/h transdermal patch
victanyl 100 micrograms/h transdermal patch
actavis group ptc ehf - Фентанил - 100 micrograms/h transdermal patch
fentanyl-richter 50 micrograms/ml solution for injection
gedeon richter plc. - Фентанил - 50 micrograms/ml solution for injection